Results
laboratory abnormalities
ADVERSE EVENTS
Between August 1, 2016 and March 20, 2018, a total of 21 patients were screened, 6 of whom did not meet eligibility criteria (Baseline characteristics

At the time of the July 1, 2021 data cutoff for data collection, all 15 patients had discontinued study treatment and were deceased. There were no observed objective responses by RECIST version 1.1 in the study participants (No patients discontinued study treatment due to treatment-related adverse events (TRAE). All study participants experienced a TRAE (Treatment-related frequency of adverse events and laboratory abnormalities

